US Stock MarketDetailed Quotes

NVO Novo-Nordisk A/S

Watchlist
  • 77.870
  • -0.960-1.22%
Close Feb 14 16:00 ET
  • 78.300
  • +0.430+0.55%
Post 19:59 ET
345.79BMarket Cap24.48P/E (TTM)

About Novo-Nordisk A/S Company

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsv?rd, Denmark.

Company Profile

SymbolNVO
Company NameNovo-Nordisk A/S
Listing DateJul 9, 1981
Founded1931
CEOMr. Lars Fruergaard Jorgensen
MarketNYSE
Employees77349
Securities TypeDR
ADS Ratio1.0 : 1.0
Fiscal Year Ends12-31
AddressNovo Allé 1
CityBagsv?rd
ProvinceCapital Region
CountryDenmark
Zip Code2880
Phone45-44-44-88-88

Company Executives

  • Name
  • Position
  • Salary
  • Lars Fruergaard Jorgensen
  • Chief Executive Officer and President
  • --
  • Marcus Schindler, PhD
  • Executive Vice President, Research and Early Development and Chief Scientific Officer
  • 23.60M
  • Karsten Munk Knudsen
  • Executive Vice President and Chief Financial Officer
  • 26.40M
  • Maziar Mike Doustdar
  • Executive Vice President, International Operations
  • 2.20M
  • Henrik Ehlers Wulff
  • Executive Vice President, Product Supply, Quality Assurance, Digital Data and Information Technology
  • 25.90M
  • Ludovic Helfgott
  • Executive Vice President, Rare Disease
  • 2.20M
  • Camilla Sylvest
  • Executive Vice President, Commercial Strategy and Corporate Affairs
  • 23.40M
  • Martin Holst Lange
  • Executive Vice President, Development
  • 23.40M
  • Helge Lund
  • Chairman of the Board
  • 3.90M
  • Henrik Poulsen
  • Vice Chairman of the Board
  • 2.40M
  • Mette Bojer Jensen
  • Director
  • 1.30M
  • Thomas Rantzau
  • Director
  • 1.10M
  • Kasim Kutay
  • Director
  • 1.30M
  • Liselotte Hyveled
  • Director
  • 1.10M
  • Elisabeth Dahl Christensen
  • Director
  • 1.10M
  • Dr. Martin W. Mackay, PhD
  • Independent Director
  • 1.80M
  • Christina Law
  • Independent Director
  • 1.70M
  • Dr. Sylvie Gregoire,Pharm.D.
  • Independent Director
  • 2.00M
  • Andreas Fibig
  • Independent Director
  • 1.40M
  • Laurence Debroux
  • Independent Director
  • 2.10M
  • Tania Sabroe
  • Executive Vice President, People and Organisation
  • 2.20M
  • David Moore
  • Executive Vice President, US Operations and Business Development
  • 2.20M

Trending Stocks

Reassessing Chinese Assets
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.
Discussing
Big Tech’s earnings season in full swing! Nvidia is the only one left
On Thursday, $Amazon (AMZN.US)$ stock fell after the firm reported Q4 adjusted earnings of $1.86/share, vs estimates of $1.50/share, on reve Show More